[Abstract] Antigen presentation by MHC class I molecules, also referred to as cross-presentation, elicits cytotoxic immune responses. In particular, dendritic cells (DC) are the most proficient cross-presenting cells, since they have developed unique means to control phagocytic and degradative pathways.
14. B3Z T cell line (a Kb-restricted, OVA-specific CD8 + T cell hybridoma) (Kurts et al., 1996) 15. Low endotoxin OVA (50 mg/ml stock) (Worthington Biochemical, catalog number: LS003062) The day before the cross-presentation experiment, particles are coupled to OVA (bead-bound OVA: bbOVA). Polystyrene beads of 3 μm diameter are coated with soluble OVA and soluble BSA ranging from 100% OVA (most concentrated) to 100% BSA (background). Since BSA is not cross-presented, the preparation of beads coated with 100% BSA is the accurate control to check whether beads without any antigen coating are able to induce any additional activation of DC.
a. Estimate the amount of 3 μm beads that will be used during the cross-presentation experiment on day 0. Consider to prepare a minimum of at least four different conditions:
i. 100% OVA and 0% BSA: 10 mg/ml OVA ii. 50% OVA and 50% BSA: 5 mg/ml OVA + 5 mg/ml BSA iii. 25% OVA and 75% BSA: 2.5 mg/ml OVA + 7.5 mg/ml BSA iv. 0% OVA and 100% BSA: 10 mg/ml BSA b. Dilute the beads differentially depending on the readout. c. For the OT-I T cell proliferation readout, incubate BMDC with bbOVA for 1 h at 37 °C.
Consequently, cross-presenting BMDC are co-cultured with 60,000-100,000 CFSE-stained OT-I T cells and T cell proliferation is analyzed 72 h later (continues in step 5a). n. For T cell analysis, proceed as described before (T cell read-outs from Procedure of part I). 
